Covered recipient · General Payments record
ELEONORA TEPLINSKY
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$31,133.49
- Reported across 57 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $16,965.00 | 7 |
| Travel and Lodging | $1,410.39 | 3 |
| Food and Beverage | $357.10 | 5 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Daiichi Sankyo Inc. | $10,818.04 | 6 |
| ABBVIE INC. | $3,781.78 | 5 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $2,775.00 | 2 |
| Acerta Pharma LLC | $1,340.00 | 1 |
| Gilead Sciences, Inc. | $17.67 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $134.85 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106210320 | CMS |
| ABBVIE INC. | $27.35 | 06/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106210322 | CMS |
| ABBVIE INC. | $102.23 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106210324 | CMS |
| ABBVIE INC. | $3,300.00 | 12/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1106210326 | CMS |
| ABBVIE INC. | $217.35 | 12/18/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1106210328 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,340.00 | 11/17/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1104389477 | CMS |
| Daiichi Sankyo Inc. | $1,250.00 | 03/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089489670 | CMS |
| Daiichi Sankyo Inc. | $499.74 | 04/08/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1089489666 | CMS |
| Daiichi Sankyo Inc. | $312.50 | 04/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089489672 | CMS |
| Daiichi Sankyo Inc. | $312.50 | 07/24/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089489668 | CMS |
| Daiichi Sankyo Inc. | $7,750.00 | 08/09/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089489664 | CMS |
| Daiichi Sankyo Inc. | $693.30 | 09/04/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1089489662 | CMS |
| Gilead Sciences, Inc. | $17.67 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133794043 | CMS |
| Novartis Pharmaceuticals Corporation | $75.00 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087346560 | CMS |
| Novartis Pharmaceuticals Corporation | $2,700.00 | 12/10/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1087346562 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.